Caroline Solas

3.3k total citations
94 papers, 1.5k citations indexed

About

Caroline Solas is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Caroline Solas has authored 94 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Infectious Diseases, 26 papers in Virology and 20 papers in Epidemiology. Recurrent topics in Caroline Solas's work include HIV/AIDS drug development and treatment (43 papers), HIV Research and Treatment (26 papers) and Hepatitis C virus research (19 papers). Caroline Solas is often cited by papers focused on HIV/AIDS drug development and treatment (43 papers), HIV Research and Treatment (26 papers) and Hepatitis C virus research (19 papers). Caroline Solas collaborates with scholars based in France, United Kingdom and Belgium. Caroline Solas's co-authors include Bruno Lacarelle, Alain Lafeuillade, Philippe Halfon, Gilles Hittinger, Isabelle Poizot‐Martin, Sylvie Quaranta, Philippe Colson, Romain Guilhaumou, Anne Motte and Patrick Borentain and has published in prestigious journals such as Nature Communications, PLoS ONE and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Caroline Solas

89 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Caroline Solas France 23 920 430 258 246 212 94 1.5k
Polina German United States 20 905 1.0× 272 0.6× 425 1.6× 424 1.7× 377 1.8× 36 1.9k
Joaquin Valdes United States 16 1.1k 1.2× 887 2.1× 453 1.8× 357 1.5× 134 0.6× 31 2.6k
Geoffrey J. Yuen United States 22 1.0k 1.1× 629 1.5× 416 1.6× 219 0.9× 144 0.7× 39 1.5k
Julie Borland United States 26 1.3k 1.4× 759 1.8× 339 1.3× 111 0.5× 309 1.5× 52 2.0k
Margo Heath‐Chiozzi United States 13 852 0.9× 801 1.9× 265 1.0× 111 0.5× 175 0.8× 22 1.7k
Anne‐Marie Taburet France 26 1.5k 1.6× 818 1.9× 406 1.6× 137 0.6× 155 0.7× 74 2.1k
Joseph M. Custodio United States 18 1.4k 1.5× 874 2.0× 234 0.9× 135 0.5× 247 1.2× 40 2.0k
Judit Morelló Portugal 20 561 0.6× 285 0.7× 331 1.3× 274 1.1× 153 0.7× 55 1.1k
Mauro Sciandra Italy 26 1.0k 1.1× 707 1.6× 488 1.9× 303 1.2× 214 1.0× 53 1.7k
Lorena Baietto Italy 27 826 0.9× 323 0.8× 349 1.4× 227 0.9× 233 1.1× 61 1.6k

Countries citing papers authored by Caroline Solas

Since Specialization
Citations

This map shows the geographic impact of Caroline Solas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Solas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Solas more than expected).

Fields of papers citing papers by Caroline Solas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline Solas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Solas. The network helps show where Caroline Solas may publish in the future.

Co-authorship network of co-authors of Caroline Solas

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline Solas. A scholar is included among the top collaborators of Caroline Solas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline Solas. Caroline Solas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Geretti, Anna María, Marta Boffito, Stefano Bonora, et al.. (2025). Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. Open Forum Infectious Diseases. 12(7). ofaf368–ofaf368. 2 indexed citations
2.
Touret, Franck, Jean‐Sélim Driouich, Maxime Cochin, et al.. (2024). Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns. Heliyon. 10(10). e30862–e30862. 2 indexed citations
3.
Martin, Edouard, et al.. (2023). Transdermal Nicotine Poisoning: A Rare Case Report of Occupational Exposure. Toxics. 11(5). 464–464. 3 indexed citations
4.
Solas, Caroline, et al.. (2023). 22 Favipiravir pharmacokinetics in immunocompromised infants and children with chronic RNA viral infections. Archives of Disease in Childhood. 108(6). A7.3–A8. 1 indexed citations
5.
Lemaı̂tre, F., Marie‐Claude Gagnieu, François Parant, et al.. (2023). Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV‐1‐infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS‐MIE‐BIRIDER study). British Journal of Clinical Pharmacology. 90(1). 264–273.
6.
Carvelli, Julien, Luc de Haro, Robert Gilli, et al.. (2021). Tentative de suicide par intoxication au laurier rose traitée par anticorps antidigitaliques. Annales de Toxicologie Analytique. 33(2). 141–146. 1 indexed citations
7.
Lê, Minh, Naïm Bouazza, Florence Gattacceca, et al.. (2020). Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV‐infected patients. British Journal of Clinical Pharmacology. 86(12). 2404–2413. 9 indexed citations
8.
Marie, B. De Sainte, Caroline Solas, Pierre‐Emmanuel Morange, et al.. (2019). Nécrose hémorragique bilatérale des surrénales sous apixaban : penser au syndrome des antiphospholipides ?. La Revue de Médecine Interne. 41(7). 489–492. 2 indexed citations
9.
El‐Sherif, Omar, Saye Khoo, & Caroline Solas. (2015). Key drug–drug interactions with direct-acting antiviral in HIV–HCV coinfection. Current Opinion in HIV and AIDS. 10(5). 348–354. 33 indexed citations
10.
Spano, Jean‐Philippe, Isabelle Poizot‐Martin, Dominique Costagliola, et al.. (2015). Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. Annals of Oncology. 27(3). 397–408. 30 indexed citations
11.
Morand‐Joubert, Laurence, Jade Ghosn, Constance Delaugerre, et al.. (2012). Lack of benefit of 3‐month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: The INNOVE study. Journal of Medical Virology. 84(11). 1710–1718. 4 indexed citations
12.
Dominguez, Stéphanie, Jade Ghosn, Giovanna Melica, et al.. (2012). Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV. Journal of Antimicrobial Chemotherapy. 67(6). 1449–1452. 9 indexed citations
13.
Urien, Saı̈k, Ghislaine Firtion, Suzanne T. Anderson, et al.. (2011). Lopinavir/ritonavir population pharmacokinetics in neonates and infants. British Journal of Clinical Pharmacology. 71(6). 956–960. 25 indexed citations
14.
Muret, Patrice, et al.. (2011). Niveau de preuve du suivi therapeutique pharmacologique de la névirapine. Therapies. 66(3). 187–195. 3 indexed citations
15.
16.
Henry, Mireille, et al.. (2008). VERTICAL TRANSMISSION OF MULTIDRUG-RESISTANT Q151M HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 STRAINS. The Pediatric Infectious Disease Journal. 27(3). 278–280. 6 indexed citations
17.
Solas, Caroline, Philippe Colson, Isabelle Ravaux, et al.. (2008). The Genotypic Inhibitory Quotient. JAIDS Journal of Acquired Immune Deficiency Syndromes. 48(2). 177–180. 15 indexed citations
18.
Solas, Caroline, Nicolas Simon, Sylvie Quaranta, et al.. (2007). Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV‐infected patients. British Journal of Clinical Pharmacology. 64(3). 353–362. 32 indexed citations
19.
Solas, Caroline, et al.. (2002). Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data. Pathologie Biologie. 50(9). 565–567. 1 indexed citations
20.
Lafeuillade, Alain, et al.. (2002). Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: Clinical correlations. HIV Clinical Trials. 3(1). 27–35. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Polina German Breakdown of academic impact, for papers by Joaquin Valdes Breakdown of academic impact, for papers by Geoffrey J. Yuen Breakdown of academic impact, for papers by Julie Borland Breakdown of academic impact, for papers by Margo Heath‐Chiozzi Breakdown of academic impact, for papers by Anne‐Marie Taburet Breakdown of academic impact, for papers by Joseph M. Custodio Breakdown of academic impact, for papers by Judit Morelló Breakdown of academic impact, for papers by Mauro Sciandra Breakdown of academic impact, for papers by Lorena Baietto
Rankless by CCL
2026